Menu Search
Equities

Innovent Biologics Inc

1801N:MEX

Innovent Biologics Inc

Actions
  • Price (MXN)111.15
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Jan 27 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Innovent Biologics Inc grew revenues 36.21% from 4.56bn to 6.21bn while net income improved from a loss of 2.18bn to a smaller loss of 1.03bn.
Gross margin81.69%
Net profit margin-16.56%
Operating margin-16.85%
Return on assets-5.38%
Return on equity-8.84%
Return on investment-6.80%
More ▼

Cash flow in CNYView more

In 2023, Innovent Biologics Inc increased its cash reserves by 170.20%, or 1.73bn. Cash Flow from Financing totalled 2.59bn or 41.69% of revenues. In addition the company generated 147.81m in cash from operations while cash used for investing totalled 998.66m.
Cash flow per share-0.4466
Price/Cash flow per share--
Book value per share8.37
Tangible book value per share7.52
More ▼

Balance sheet in CNYView more

Innovent Biologics Inc has a Debt to Total Capital ratio of 22.42%, a higher figure than the previous year's 21.57%.
Current ratio3.00
Quick ratio2.78
Total debt/total equity0.289
Total debt/total capital0.2242
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.